Medicare Part D coverage · atovaquone · RxCUI 211947

atovaquone 150 MG/ML Oral Suspension [Mepron]

Per the CMS 2026 Part D formulary file, atovaquone 150 MG/ML Oral Suspension [Mepron] is covered by 6 Medicare Part D plans (0.1% of enrollable products), averaging Tier 5, with prior authorization required on 0% of covering formularies.

0.1%
Plan coverage
6
Plans covering
T5
Avg tier
0%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for atovaquone 150 MG/ML Oral Suspension [Mepron]

Per the CMS 2026 Part D formulary file, atovaquone 150 MG/ML Oral Suspension [Mepron] (RxNorm concept RXCUI 211947, generic name atovaquone) appears on 1 distinct formulary file spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 5 to Tier 5, with a cross-plan average of Tier 5.

Real-world access to atovaquone 150 MG/ML Oral Suspension [Mepron] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 21,829 Part D beneficiaries filled atovaquone 150 MG/ML Oral Suspension [Mepron] in 2023, with total plan-and-beneficiary spending of $53,394,312 and an average per-beneficiary annual cost of $2,446.03. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry atovaquone 150 MG/ML Oral Suspension [Mepron] today.

Coverage Details

Formularies covering
1
Plans covering
6
Coverage rate
0.1%
Tier range
Tier 5, Specialty
Average tier
Tier 5, Specialty

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
21,829
Total spending
$53,394,312
Avg per beneficiary
$2,446.03

Tier Distribution Across Plans

6 plans
Tier 5, Specialty

Medicare Advantage Plans (MA-PD) Covering atovaquone 150 MG/ML Oral Suspension [Mepron]

6 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Óptimo Plus (PPO) Triple S Advantage, Inc. T5 No $0 PR
Contigo Plus (HMO C-SNP) Triple S Advantage, Inc. T5 No $0 PR
Brillante (HMO-POS) Triple S Advantage, Inc. T5 No $0 PR
Enlace Plus (HMO) Triple S Advantage, Inc. T5 No $0 PR
ContigoEnMente (HMO C-SNP) Triple S Advantage, Inc. T5 No $0 PR
Ahorro Plus (HMO) Triple S Advantage, Inc. T5 No $0 PR

Frequently Asked Questions

Is atovaquone 150 MG/ML Oral Suspension [Mepron] covered by Medicare Part D?

Yes, atovaquone 150 MG/ML Oral Suspension [Mepron] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).

What tier is atovaquone 150 MG/ML Oral Suspension [Mepron] on Medicare Part D plans?

atovaquone 150 MG/ML Oral Suspension [Mepron] averages Tier 5 across Part D plans, ranging from Tier 5 to Tier 5.

Does atovaquone 150 MG/ML Oral Suspension [Mepron] require prior authorization?

0% of Part D formularies require prior authorization for atovaquone 150 MG/ML Oral Suspension [Mepron]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on atovaquone 150 MG/ML Oral Suspension [Mepron]?

In 2023, total Medicare Part D spending on atovaquone 150 MG/ML Oral Suspension [Mepron] was $53,394,312, covering 21,829 beneficiaries. The average spend per beneficiary was $2,446.03.

Read our methodology - how this data is sourced, computed, and verified.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Closest average formulary tier

Similar prior-authorization rate

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare